share_log

Sutro Biopharma Doses First Patient on Ovarian Cancer Treatment Study

Dow Jones Newswires ·  Jan 21, 2021 21:16

DJ Sutro Biopharma Doses First Patient on Ovarian Cancer Treatment Study

By Chris Wack

Sutro Biopharma Inc. said Thursday it has dosed the first patient in the dose-expansion cohort of its Phase 1 STRO-002 study.

STRO-002 is a folate receptor alpha targeting antibody-drug conjugate for the potential treatment of ovarian cancer.

The company said the dose-expansion cohort will assess the efficacy, safety and tolerability of STRO-002 at 4.3 and 5.2 mg/kg, given every three weeks in patients with ovarian cancer. The dose-expansion cohort for folate receptor alpha-selected endometrial cancer is planned for later this year.

Sutro said it plans to expand the study to 35 clinical sites in the U.S. and Europe. The dose-expansion study includes two patient cohorts, advanced epithelial ovarian cancer and endometrial cancer.

Sutro Biopharma shares were up 17% to $30.86 in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

January 21, 2021 08:16 ET (13:16 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment